![]() ALLO-501A was reported to have a similar safety and efficacy profile. No graft-vs-host disease (GvHD) was observed, with only low rates of neurotoxicity and cytokine release syndrome. ![]() ALLO-501, a CD19-targeting CAR-T programme with T-cell receptor (TCR) and CD52 knock-out demonstrated an overall response rate (ORR) of 75%, with a complete response (CR) rate of 50%. The presented data set is one of the most comprehensive for an allogeneic CAR-T programme. These data will be presented at the American Society of Clinical Oncology (ASCO) annual meeting in June. On May 19th, Allogene Therapeutics (NASDAQ: ALLO) reported updated interim data for its ALLO-501/ALLO-501A CAR-T programmes. On the first trading day after Fate released its Phase 1 data, its stock increased by 14% at its highest from $68.98 to $78.68.Īllogene Therapeutics with new allogeneic CAR-T data None of the treatments showed dose-limiting toxicity or cytokine release syndrome (CRS). Of these three patients, one achieved objective response with complete leukaemic blast clearance in the bone marrow. For the FT538 drug, three patients are being treated in the first dose escalation cohort. Though the data did not trigger a noticeable rise in the BEAM stock, it serves as a promising proof-of-concept of Verve’s base-editing technology.įate Therapeutics publishes new CAR-NK dataįate therapeutics (NASDAQ: FATE) announced encouraging data on its Phase 1 iPSC-derived NK-cells, in the after hours of the stock market. In addition, the effects of the treatment lasted for 8 months after administration of a single dose. The company observed a near complete knockdown of the PCSK9 gene in the liver and observed subsequent reduction of PCSK9 protein and low-density-lipoprotein cholesterol of 90% and 60% reduction, respectively. The CRISPR base editor was administered using a LNP formulation to non-human primates. The data was published in the highly profiled journal, Nature. On May 19th, Verve Therapeutics, with support from Beam Therapeutics, announced proof-of-concept data on its base-editing approach for the treatment of cardiovascular disease. Verve Therapeutics demonstrates preclinical proof-of-concept with support from Beam Therapeutics The Precision Biosciences (NASDAQ: DTIL) stock has had an impressive month, with the highest gain out of all the stocks represented in the CMN Markets graph (Figure 1). The company develops the ARCUS system to treat transthyretin amyloidosis by knock-out of the transthyretin gene, delivered by an adeno-associated viral (AAV) vector. On May 11th Precision presented positive updates on the use of their ARCUS platform for one time gene-editing treatments. In the same report, BEAM gave an update on their plans to submit an IND on the BEAM-101 programme and initiate IND-enabling studies for their BEAM-102 and BEAM-201 programmes. Beam Therapeutics (NASDAQ: BEAM) posted an update on its proprietary lipid nanoparticle (LNP) formulation, showing efficient in vivo base editing in non-human primates. ![]() Many larger gene-editing companies presented their data readouts with positive results. The American Society of Gene and Cell Therapy (ASGCT) annual meeting took place virtually from May 11th to May 14th. Despite the grim outlooks from the first half of May, biotech seems to be slowly regaining traction as can be seen in Figure 1.Īmerican Society of Gene and Cell Therapy annual meeting Additionally, David Kelly, the chief global strategist at JP Morgan Asset Management spoke on inflation, saying: “ higher inflation may be stickier than the Fed expects”. Brian Vendig, the president of MJP Wealth Advisors told Reuters: “ The uncertainty over the path of rates and inflation is making investors reconsider their portfolios, especially in technology stocks”, reiterating the influence that rising inflation has on technology stocks, in which biotech companies are included. consumer price data from April showed the highest rise in prices since 2009. Biotech stock prices dropped fairly consistently from May 1st until May 13th where the Nasdaq Biotech index fell to lows matching November 2020. As reported by CNBC, inflation “ could weigh on stocks as inflation erodes the value of future company profits”. At the annual Berkshire Hathaway meeting, Warren Buffett reported seeing “ very substantial inflatio n” from suppliers. In early May, inflation reports showed that inflation was higher than expected. Influences from the broader economic trends CMN Webinar - CRISPR-based Control of Insect-borne Diseases.CMN Webinar - Controllable Genome Editing With Split-Engineered Base Editors.CMN Webinar - Deliver CRISPR to the Brain - A New Treatment Strategy for Mucopolysaccharidoses.Shanghai Bangyao Biotechnology Co., Ltd.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |